KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $5.2 million.

  • Nektar Therapeutics' Other Non-Current Assets fell 84.40% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 84.40%. This contributed to the annual value of $4.6 million for FY2024, which is 0.06% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Other Non-Current Assets of $5.2 million as of Q3 2025, which was up 2.63% from $5.0 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Other Non-Current Assets high stood at $33.1 million for Q3 2024, and its period low was $344,000 during Q2 2021.
  • In the last 3 years, Nektar Therapeutics' Other Non-Current Assets had a median value of $4.6 million in 2024 and averaged $6.8 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 630.78% in 2024, then crashed by 84.40% in 2025.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Other Non-Current Assets stood at $2.7 million in 2021, then fell by 18.19% to $2.2 million in 2022, then skyrocketed by 106.86% to $4.6 million in 2023, then rose by 0.06% to $4.6 million in 2024, then slumped by 84.40% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $5.0 million for Q2 2025, and $5.4 million during Q1 2025.